103.22
price up icon1.45%   1.48
pre-market  Pre-market:  103.00   -0.22   -0.21%
loading
Neurocrine Biosciences Inc stock is traded at $103.22, with a volume of 1.93M. It is up +1.45% in the last 24 hours and down -7.77% over the past month.
See More
Previous Close:
$101.74
Open:
$103.61
24h Volume:
1.93M
Relative Volume:
1.32
Market Cap:
$9.39B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
27.67
EPS:
3.73
Net Cash Flow:
$440.10M
1W Performance:
+3.12%
1M Performance:
-7.77%
6M Performance:
-10.31%
1Y Performance:
-26.32%
1-Day Range:
Value
$102.43
$106.20
1-Week Range:
Value
$98.95
$106.20
52-Week Range:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
103.22 9.39B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
150.91 65.46B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.18 46.11B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.23 45.84B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
14.29 16.37B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
293.46 12.81B 2.76B 1.11B 898.10M 22.77

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Upgrade Needham Hold → Buy
Apr-14-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-11-25 Initiated Deutsche Bank Hold
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
Apr 23, 2025

Neurocrine (NBIX) Target Price Lowered by H.C. Wainwright Due to Market Pressures | NBIX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 22, 2025

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 - Seeking Alpha

Apr 22, 2025
pulisher
Apr 22, 2025

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case - Yahoo Finance

Apr 22, 2025
pulisher
Apr 21, 2025

Neurocrine Biosciences director sells shares worth $21.8 million - MSN

Apr 21, 2025
pulisher
Apr 20, 2025

Neurocrine upgraded at RBC Capital Markets on recent selloff - MSN

Apr 20, 2025
pulisher
Apr 18, 2025

Do Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Warrant Your Attention? - simplywall.st

Apr 18, 2025
pulisher
Apr 17, 2025

(NBIX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (NBIX) - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

Needham Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq

Apr 16, 2025
pulisher
Apr 15, 2025

Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

What 16 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Needham Upgrades Neurocrine Biosciences (NBIX) - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target - marketscreener.com

Apr 15, 2025
pulisher
Apr 14, 2025

RBC Capital Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Capital lifts Neurocrine Bio. stock rating to Outperform By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine Earnings Preview: Leading Neuroscience Firm to Reveal Q1 2025 Performance - Stock Titan

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Capital Upgrades Neurocrine Biosciences (NBIX) - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine stock upgraded at RBC Capital Markets (NBIX:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

RBC upgrades Neurocrine Biosciences on low tariff exposure for key drug - TradingView

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138 - MarketScreener

Apr 14, 2025
pulisher
Apr 09, 2025

Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

Apr 09, 2025
pulisher
Apr 08, 2025

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Tourette Syndrome Treatment Market Generated Opportunities, - openPR.com

Apr 08, 2025
pulisher
Apr 05, 2025

Neurocrine Biosciences names Sanjay Keswani as chief medical officer - MSN

Apr 05, 2025
pulisher
Apr 05, 2025

Neurocrine Biosciences names new Chief Medical Officer By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

NBIXNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - ADVFN

Apr 04, 2025
pulisher
Apr 04, 2025

Ex-Dyne team members reconvene at Crescent - biocentury.com

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints New Chief Medical Officer - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

UBS cuts Neurocrine Bio. stock target to $137, keeps Buy rating - Investing.com Canada

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences appoints new chief medical officer - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medi - GuruFocus

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences names new Chief Medical Officer - Investing.com India

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer - Contract Pharma

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer - marketscreener.com

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer - StreetInsider

Apr 04, 2025
pulisher
Apr 04, 2025

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer – Company Announcement - Financial Times

Apr 04, 2025
pulisher
Apr 04, 2025

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating - MarketScreener

Apr 04, 2025
pulisher
Apr 03, 2025

Neurocrine Biosci stock hits 52-week low at $105.17 By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Neurocrine Biosci stock hits 52-week low at $105.17 - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - The Globe and Mail

Apr 03, 2025
pulisher
Apr 02, 2025

Mitsubishi UFJ Trust & Banking Corp Sells 4,578 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Neurocrine Biosciences executive sells shares worth $266,024 - MSN

Apr 02, 2025
pulisher
Mar 31, 2025

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia - PR Newswire

Mar 31, 2025
pulisher
Mar 31, 2025

New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate - Stock Titan

Mar 31, 2025
pulisher
Mar 29, 2025

Supporting a Loved One Living with a Mental Health Condition and Tardive Dyskinesia - Main Street Media of Tennessee

Mar 29, 2025
pulisher
Mar 26, 2025

Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView

Mar 26, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$7.81
price up icon 1.56%
$101.20
price up icon 1.64%
$293.46
price up icon 0.22%
$27.15
price up icon 0.15%
drug_manufacturers_specialty_generic PBH
$79.77
price down icon 0.57%
Cap:     |  Volume (24h):